company background image
FATE

Fate Therapeutics NasdaqGM:FATE Stock Report

Last Price

US$5.96

Market Cap

US$579.1m

7D

10.4%

1Y

-84.9%

Updated

01 Feb, 2023

Data

Company Financials +

Fate Therapeutics, Inc.

NasdaqGM:FATE Stock Report

Mkt Cap: US$579.1m

FATE Stock Overview

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.

FATE fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Fate Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Fate Therapeutics
Historical stock prices
Current Share PriceUS$5.96
52 Week HighUS$43.12
52 Week LowUS$4.02
Beta1.62
1 Month Change-40.93%
3 Month Change-69.36%
1 Year Change-84.95%
3 Year Change-77.58%
5 Year Change-25.87%
Change since IPO-9.97%

Recent News & Updates

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Jan 10
We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Recent updates

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Jan 10
We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

Sep 22
Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely

Jun 02
We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely

We're Not Very Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Feb 01
We're Not Very Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Fate Therapeutics (NASDAQ:FATE) Is In A Good Position To Deliver On Growth Plans

Oct 16
Fate Therapeutics (NASDAQ:FATE) Is In A Good Position To Deliver On Growth Plans

Companies Like Fate Therapeutics (NASDAQ:FATE) Can Afford To Invest In Growth

Jul 18
Companies Like Fate Therapeutics (NASDAQ:FATE) Can Afford To Invest In Growth

This Is Why Fate Therapeutics, Inc.'s (NASDAQ:FATE) CEO Compensation Looks Appropriate

May 26
This Is Why Fate Therapeutics, Inc.'s (NASDAQ:FATE) CEO Compensation Looks Appropriate

Companies Like Fate Therapeutics (NASDAQ:FATE) Can Afford To Invest In Growth

Apr 13
Companies Like Fate Therapeutics (NASDAQ:FATE) Can Afford To Invest In Growth

Fate Therapeutics, Inc.'s (NASDAQ:FATE) Intrinsic Value Is Potentially 41% Above Its Share Price

Feb 19
Fate Therapeutics, Inc.'s (NASDAQ:FATE) Intrinsic Value Is Potentially 41% Above Its Share Price

J. Wolchko Is The Founder of Fate Therapeutics, Inc. (NASDAQ:FATE) And They Just Sold 28% Of Their Shares

Jan 15
J. Wolchko Is The Founder of Fate Therapeutics, Inc. (NASDAQ:FATE) And They Just Sold 28% Of Their Shares

Companies Like Fate Therapeutics (NASDAQ:FATE) Can Afford To Invest In Growth

Jan 01
Companies Like Fate Therapeutics (NASDAQ:FATE) Can Afford To Invest In Growth

Shareholder Returns

FATEUS BiotechsUS Market
7D10.4%-0.2%1.7%
1Y-84.9%3.9%-12.5%

Return vs Industry: FATE underperformed the US Biotechs industry which returned 1.2% over the past year.

Return vs Market: FATE underperformed the US Market which returned -13.6% over the past year.

Price Volatility

Is FATE's price volatile compared to industry and market?
FATE volatility
FATE Average Weekly Movement21.7%
Biotechs Industry Average Movement12.3%
Market Average Movement6.9%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: FATE is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 22% a week.

Volatility Over Time: FATE's weekly volatility has increased from 15% to 22% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2007545J. Wolchkohttps://www.fatetherapeutics.com

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd.

Fate Therapeutics, Inc. Fundamentals Summary

How do Fate Therapeutics's earnings and revenue compare to its market cap?
FATE fundamental statistics
Market CapUS$579.14m
Earnings (TTM)-US$293.98m
Revenue (TTM)US$69.01m

8.4x

P/S Ratio

-2.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
FATE income statement (TTM)
RevenueUS$69.01m
Cost of RevenueUS$12.99m
Gross ProfitUS$56.03m
Other ExpensesUS$350.01m
Earnings-US$293.98m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.03
Gross Margin81.18%
Net Profit Margin-425.98%
Debt/Equity Ratio0%

How did FATE perform over the long term?

See historical performance and comparison